- Home
- REGN vs NGG Comparison
REGN vs NGG Comparison
Compare REGN & NGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- NGG
- Stock Information
- Founded
- REGN 1988
- NGG 1990
- Country
- REGN United States
- NGG United Kingdom
- Employees
- REGN N/A
- NGG N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- NGG Natural Gas Distribution
- Sector
- REGN Health Care
- NGG Utilities
- Exchange
- REGN Nasdaq
- NGG Nasdaq
- Market Cap
- REGN 63.4B
- NGG 71.4B
- IPO Year
- REGN 1991
- NGG 1999
- Fundamental
- Price
- REGN $527.78
- NGG $70.73
- Analyst Decision
- REGN Buy
- NGG Hold
- Analyst Count
- REGN 23
- NGG 2
- Target Price
- REGN $907.39
- NGG N/A
- AVG Volume (30 Days)
- REGN 1.3M
- NGG 960.9K
- Earning Date
- REGN 04-29-2025
- NGG 05-22-2025
- Dividend Yield
- REGN 0.33%
- NGG 9.93%
- EPS Growth
- REGN 16.49
- NGG N/A
- EPS
- REGN 39.43
- NGG 0.59
- Revenue
- REGN $14,085,700,000.00
- NGG $25,897,332,788.00
- Revenue This Year
- REGN $2.38
- NGG N/A
- Revenue Next Year
- REGN $7.65
- NGG $1.68
- P/E Ratio
- REGN $13.39
- NGG $28.33
- Revenue Growth
- REGN 7.52
- NGG N/A
- 52 Week Low
- REGN $525.99
- NGG $55.13
- 52 Week High
- REGN $1,211.20
- NGG $74.82
- Technical
- Relative Strength Index (RSI)
- REGN 35.08
- NGG 52.94
- Support Level
- REGN $520.50
- NGG $70.06
- Resistance Level
- REGN $615.61
- NGG $72.75
- Average True Range (ATR)
- REGN 22.65
- NGG 0.87
- MACD
- REGN -2.54
- NGG -0.48
- Stochastic Oscillator
- REGN 7.65
- NGG 14.08
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About NGG National Grid Transco PLC National Grid PLC (NEW)
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.